Cargando…

IgG Antibody Response to the Pfizer BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers with Healthy Weight, Overweight, and Obesity

Obesity is a significant factor for increased morbidity and mortality upon infection with SARS-CoV-2. Because of the higher potential for negative outcomes following infection of individuals with obesity, the impact of body mass index (BMI) on vaccine immunogenicity and efficacy is an important publ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bates, John T., Farmer, Andrew P., Bierdeman, Michael A., Ederer, Dallas R., Carney, Lauren S., Montgomery, Denise D., Lirette, Seth T., Marshall, Gailen D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025933/ https://www.ncbi.nlm.nih.gov/pubmed/35455261 http://dx.doi.org/10.3390/vaccines10040512

Ejemplares similares

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
por: Cele, Sandile, et al.
Publicado: (2021)

A racing heart post‐Pfizer/BioNTech BNT162b2
por: Teo, Hooi Khee, et al.
Publicado: (2022)

Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine
por: Li, Chunfeng, et al.
Publicado: (2022)

Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
por: Hamada, Yohhei
Publicado: (2021)

Potential Triggers for Thrombocytopenia and/or Hemorrhage by the BNT162b2 Vaccine, Pfizer-BioNTech
por: Okada, Yusuke, et al.
Publicado: (2021)

Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022)

Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine
por: Kobashi, Yurie, et al.
Publicado: (2022)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

Syncope following Pfizer BioNTech (bnt162b2) vaccination unmasking Brugada syndrome
por: Altermanini, Mohammad, et al.
Publicado: (2023)

Efficacy of Vaccine BNT162b2 (Pfizer-BioNTech) in Individuals with Waldenstrom's Macroglobulinemia and Follicular Lymphoma in Australia
por: Beaton, Brendan, et al.
Publicado: (2021)

Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination
por: Matsubara, Akihiro, et al.
Publicado: (2021)

POS-928 EFFICACY OF THE PFIZER/ BNT162b2 COVID-19 VACCINE IN PERITONEAL DIALYSIS PATIENTS
por: BEIRÃO, B., et al.
Publicado: (2022)

Response to and outcomes of the Pfizer BNT162B2 vaccine in hemodialysis patients—A prospective observational study
por: Al‐Muhaiteeb, Abdullah, et al.
Publicado: (2022)

Pfizer BNT 162b2 COVID-19 vaccine–induced fulminant myopericarditis: A case study
por: Montarello, Natalie L., et al.
Publicado: (2023)

Effect of Heterologous Vaccination Regimen with Ad5-nCoV CanSinoBio and BNT162b2 Pfizer in SARS-CoV-2 IgG Antibodies Titers †
por: Romero-Ibarguengoitia, Maria Elena, et al.
Publicado: (2022)

Severe hyponatraemia with cerebral oedema after Pfizer BNT162b2 mRNA vaccination against COVID-19
por: Dharma, J.F.M., et al.
Publicado: (2023)

Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine: historical cohort study
por: Shasha, David, et al.
Publicado: (2022)

Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination
por: Grupel, Daniel, et al.
Publicado: (2021)

Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis
por: Jahn, Michael, et al.
Publicado: (2021)

Cerebral Venous Sinus Thrombosis After Pfizer-BioNTech COVID-19 (BNT162b2) Vaccination
por: Cheng, Newman
Publicado: (2021)

Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer‐BioNTech)
por: Sumi, Toshiyuki, et al.
Publicado: (2021)

Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
por: Akiyama, Hiroaki, et al.
Publicado: (2021)

Vulvar Aphthous Ulcer in an Adolescent After Pfizer-BioNTech (BNT162b2) COVID-19 Vaccination
por: Wojcicki, Anna V., et al.
Publicado: (2022)

Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) Side Effects: A Systematic Review
por: Dighriri, Ibrahim M, et al.
Publicado: (2022)

Development of Flat Warts on the Cheeks after BioNTech-Pfizer BNT162b2 Vaccine: Is There a Correlation?
por: Cazzato, Gerardo, et al.
Publicado: (2022)

Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
por: Shimazawa, Rumiko, et al.
Publicado: (2021)

Pulmonary Embolism after Vaccination with the COVID-19 Vaccine (Pfizer, BNT162b2): A Case Report
por: Kim, Eun-Ju, et al.
Publicado: (2023)

Anaphylatoxin Complement 5a in Pfizer BNT162b2-Induced Immediate-Type Vaccine Hypersensitivity Reactions
por: Lim, Xin Rong, et al.
Publicado: (2023)

Comparison of Kinetics of Antibody Avidity and IgG Subclasses’ Response in Patients with COVID-19 and Healthy Individuals Vaccinated with the BNT162B2 (Comirnaty, Pfizer/BioNTech) mRNA Vaccine
por: Rastawicki, Waldemar, et al.
Publicado: (2023)

Evaluation of hematological parameters and thrombocytopenia following Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccination
por: Algaissi, Abdullah, et al.
Publicado: (2022)

Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders
por: Sauerwein, Kai M.T., et al.
Publicado: (2023)

Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees
por: Low, Jia Ming, et al.
Publicado: (2021)

POS-923 RESPONSE TO AND OUTCOMES OF THE Pfizer BNT162B2 VACCINE IN HEMODIALYSIS PATIENTS- A PROSPECTIVE OBSERVATIONAL STUDY
por: AlMuhaiteeb, A., et al.
Publicado: (2022)

Decline of Humoral Responses 6 Months after Vaccination with BNT162b2 (Pfizer–BioNTech) in Patients on Hemodialysis
por: Jahn, Michael, et al.
Publicado: (2022)

Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community
por: Abukhalil, Abdallah Damin, et al.
Publicado: (2023)

Effectiveness of the BNT162b2 (Pfizer-BioNTech) Vaccine in Children and Adolescents: A Systematic Review and Meta-Analysis
por: Sabu, Jewel Maria, et al.
Publicado: (2022)

Intracranial Hemorrhage After Pfizer-BioNTech (BNT162b2) mRNA COVID-19 Vaccination: A Case Report
por: Yangi, Kivanc, et al.
Publicado: (2023)

Re: Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine, historical cohort study: authors' response
por: Shasha, David, et al.
Publicado: (2022)

T-cell response to 3 doses of Sars-Cov2 BNT162b2 Pfizer vaccine in long term rituximab treated patients
por: Heitz, Jade, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ilo8b8uv7o5k2qmgusa7k7ksun